TG6050, an oncolytic vaccinia virus encoding interleukin-12 and anti-CTLA-4 antibody, favors tumor regression via profound immune remodeling of the tumor microenvironment

Background TG6050 was designed as an improved oncolytic vector, combining the intrinsic properties of vaccinia virus to selectively replicate in tumors with the tumor-restricted expression of recombinant immune effectors to modify the tumor immune phenotype. These properties might be of particular i...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Laetitia Fend, Eric Quemeneur, Jean-Baptiste Marchand, Nathalie Silvestre, Johann Foloppe, Christelle Remy, Patricia Kleinpeter, Jules Deforges, Fadi Azar, Christelle Demeusoit, Clémentine Spring-Giusti
Formato:	Artigo
Idioma:	Inglês
Publicado em:	BMJ Publishing Group 2024-07-01
coleção:	Journal for ImmunoTherapy of Cancer
Acesso em linha:	https://jitc.bmj.com/content/12/7/e009302.full
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!